Hutchmed China Ltd ADR (HCM)

$15.62 -0.43 (-2.68%)
Market Cap 2.80B
Revenue (ttm) 630.20M
Net Income (ttm) 37.73M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 30.22
Profit Margin 5.99%
Debt to Equity Ratio 0.08
Volume 21,900
Avg Vol 38,998
Day's Range N/A - N/A
Shares Out 174.47M
Stochastic %K 90%
Beta 0.42
Analysts Sell
Price Target $21.44

Company Profile

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. The company offers Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 852 2121 8200
Fax: 852 2128 1778
Address:
Cheung Kong Center, 48th floor 2 Queen's Road Central, Hong Kong, Hong Kong
topstockalerts
topstockalerts Jan. 7 at 3:25 PM
HUTCHMED announced that its Phase III ESLIM-02 trial of sovleplenib met its primary endpoint in adults with warm autoimmune hemolytic anemia (wAIHA) in China. The study showed a durable hemoglobin response between weeks 5 and 24 in patients who had relapsed or were refractory to at least one prior standard therapy. Sovleplenib, a novel spleen tyrosine kinase inhibitor, builds on strong Phase II data that demonstrated significantly higher response rates versus placebo. wAIHA is a rare but serious autoimmune disorder with limited treatment options. Investigators noted the drug’s potential to deliver rapid and sustained hemoglobin improvements. HUTCHMED plans to submit a New Drug Application for sovleplenib in wAIHA to China’s regulator in the first half of 2026 and is also advancing the drug for immune thrombocytopenia, with another NDA planned in the same timeframe. $HCM
0 · Reply
OpenOutcrier
OpenOutcrier Jan. 7 at 1:43 PM
$HCM (+5.1% pre) Hutchmed’s sovleplenib meets primary endpoint in wAIHA trial https://ooc.bz/l/88877
0 · Reply
briefingcom
briefingcom Jan. 7 at 1:31 PM
$HCM: HUTCHMED reports topline results of Phase III Part of ESLIM-02 Trial of Sovleplenib for warm antibody autoimmune hemolytic anemia in China
0 · Reply
JurisdictionJ
JurisdictionJ Dec. 27 at 9:40 AM
$HCM Sentiment increasingly tracks operational truth rather than guidance tone. Operational cadence needs to tighten meaningfully. Durability across environments would extend investor horizons. Patience is warranted — but must be supported by results.
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 12 at 10:14 AM
$HCM Current Stock Price: $13.65 Contracts to trade: $17.5 HCM Dec 19 2025 Call Entry: $2.34 Exit: $3.65 ROI: 56% Hold ~26 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
QueenofSouth
QueenofSouth Dec. 11 at 11:03 PM
$HCM 10
0 · Reply
QueenofSouth
QueenofSouth Dec. 11 at 11:02 PM
$HCM 9
0 · Reply
QueenofSouth
QueenofSouth Dec. 11 at 11:02 PM
$HCM 8
0 · Reply
QueenofSouth
QueenofSouth Dec. 11 at 11:02 PM
$HCM 7
0 · Reply
QueenofSouth
QueenofSouth Dec. 11 at 11:02 PM
$HCM 6
0 · Reply
Latest News on HCM
HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet

Jan 13, 2026, 11:00 PM EST - 6 days ago

HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet

Positive China Trial Data Moves HUTCHMED Closer To Rare Blood Disorder Drug Filing In 2026

Jan 7, 2026, 9:17 AM EST - 13 days ago

Positive China Trial Data Moves HUTCHMED Closer To Rare Blood Disorder Drug Filing In 2026

HUTCHMED Announces Positive Topline Results of Phase III Part of ESLIM-02 Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China

Jan 6, 2026, 7:00 PM EST - 14 days ago

HUTCHMED Announces Positive Topline Results of Phase III Part of ESLIM-02 Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China

HUTCHMED Initiates Phase III Stage of the Ongoing Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma

Jan 4, 2026, 7:00 PM EST - 16 days ago

HUTCHMED Initiates Phase III Stage of the Ongoing Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma

HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Savolitinib for the treatment of Gastric Cancer Patients with MET Amplification

Dec 30, 2025, 5:00 AM EST - 21 days ago

HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Savolitinib for the treatment of Gastric Cancer Patients with MET Amplification

HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Fanregratinib in Second-Line Intrahepatic Cholangiocarcinoma

Dec 29, 2025, 3:35 AM EST - 22 days ago

HUTCHMED Announces NDA Acceptance in China with Priority Review Status for Fanregratinib in Second-Line Intrahepatic Cholangiocarcinoma

HUTCHMED Initiates Global Clinical Development of ATTC Candidate HMPL-A251 in Patients with Solid Tumors

Dec 16, 2025, 7:00 PM EST - 5 weeks ago

HUTCHMED Initiates Global Clinical Development of ATTC Candidate HMPL-A251 in Patients with Solid Tumors

HUTCHMED Highlights Clinical Data to be Presented at the 2025 ESMO Asia Congress and the 2025 ASH Annual Meeting

Nov 26, 2025, 7:00 PM EST - 7 weeks ago

HUTCHMED Highlights Clinical Data to be Presented at the 2025 ESMO Asia Congress and the 2025 ASH Annual Meeting

HUTCHMED (China) Limited (HCM) HUTCHMED (China) Limited Presents at Deutsche Bank ADR Virtual Investor Conference 2025 Transcript

Nov 4, 2025, 3:56 PM EST - 2 months ago

HUTCHMED (China) Limited (HCM) HUTCHMED (China) Limited Presents at Deutsche Bank ADR Virtual Investor Conference 2025 Transcript

HUTCHMED Highlights Pipeline and Business Progress at R&D Updates Event

Nov 2, 2025, 7:00 PM EST - 2 months ago

HUTCHMED Highlights Pipeline and Business Progress at R&D Updates Event

HUTCHMED (China) Limited (HCM) Discusses Antibody Targeted Therapy Conjugates Platform and Lead Candidate HMPL-A251 in R&D Update Transcript

Oct 31, 2025, 7:36 PM EDT - 2 months ago

HUTCHMED (China) Limited (HCM) Discusses Antibody Targeted Therapy Conjugates Platform and Lead Candidate HMPL-A251 in R&D Update Transcript

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

Oct 14, 2025, 4:30 AM EDT - 3 months ago

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

HUTCHMED Highlights FRUSICA-2 Registration Trial Data to be Presented at the 2025 ESMO Congress

Oct 13, 2025, 12:00 AM EDT - 3 months ago

HUTCHMED Highlights FRUSICA-2 Registration Trial Data to be Presented at the 2025 ESMO Congress

HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2025

Oct 1, 2025, 8:00 PM EDT - 3 months ago

HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2025

Save the Date: HUTCHMED to Present R&D Updates on October 31, 2025

Sep 11, 2025, 8:00 PM EDT - 4 months ago

Save the Date: HUTCHMED to Present R&D Updates on October 31, 2025

HUTCHMED Highlights Clinical Data to be Presented at the 2025 World Conference of Lung Cancer and the CSCO Annual Meeting 2025

Sep 4, 2025, 8:00 PM EDT - 4 months ago

HUTCHMED Highlights Clinical Data to be Presented at the 2025 World Conference of Lung Cancer and the CSCO Annual Meeting 2025

HUTCHMED Announces Appointment of Acting Chief Executive Officer

Aug 24, 2025, 8:20 PM EDT - 5 months ago

HUTCHMED Announces Appointment of Acting Chief Executive Officer

HUTCHMED Completes Patient Enrollment of SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China

Aug 19, 2025, 8:00 PM EDT - 5 months ago

HUTCHMED Completes Patient Enrollment of SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China

HUTCHMED (China) Limited (HCM) Q2 2025 Earnings Call Transcript

Aug 8, 2025, 3:59 AM EDT - 5 months ago

HUTCHMED (China) Limited (HCM) Q2 2025 Earnings Call Transcript

HUTCHMED to Announce 2025 Half-Year Financial Results

Jul 3, 2025, 4:30 AM EDT - 7 months ago

HUTCHMED to Announce 2025 Half-Year Financial Results

HUTCHMED Announces China Approval for ORPATHYS® in Combination with TAGRISSO® for the Treatment of Lung Cancer Patients with MET Amplification After Progression on First-Line EGFR Inhibitor Therapy

Jun 30, 2025, 4:30 AM EDT - 7 months ago

HUTCHMED Announces China Approval for ORPATHYS® in Combination with TAGRISSO® for the Treatment of Lung Cancer Patients with MET Amplification After Progression on First-Line EGFR Inhibitor Therapy

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma

Jun 4, 2025, 7:45 PM EDT - 8 months ago

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma

HUTCHMED Highlights SACHI Phase III Study Data Presented at the 2025 ASCO Annual Meeting

Jun 1, 2025, 8:00 PM EDT - 8 months ago

HUTCHMED Highlights SACHI Phase III Study Data Presented at the 2025 ASCO Annual Meeting

HUTCHMED Highlights Clinical Data to be Presented at the 2025 ASCO Annual Meeting

May 22, 2025, 8:00 PM EDT - 8 months ago

HUTCHMED Highlights Clinical Data to be Presented at the 2025 ASCO Annual Meeting

HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025

Apr 23, 2025, 8:00 PM EDT - 9 months ago

HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025

HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China

Apr 21, 2025, 8:00 PM EDT - 9 months ago

HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China

HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma

Mar 21, 2025, 6:00 AM EDT - 10 months ago

HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma

Intended Retirement of Independent Non-executive Directors and changes of composition of board committees

Mar 20, 2025, 5:30 AM EDT - 10 months ago

Intended Retirement of Independent Non-executive Directors and changes of composition of board committees

US pharma restrictions won't affect Hutchmed operations, says CEO

Mar 20, 2025, 12:46 AM EDT - 10 months ago

US pharma restrictions won't affect Hutchmed operations, says CEO

HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025

Mar 19, 2025, 8:00 PM EDT - 10 months ago

HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025

HUTCHMED (China) Limited (HCM) Q4 2024 Earnings Call Transcript

Mar 19, 2025, 12:17 PM EDT - 10 months ago

HUTCHMED (China) Limited (HCM) Q4 2024 Earnings Call Transcript

Hutchmed's Oncology Revenue Hits $271.5 Million, Rising 65% On Fruzaqla Strength

Mar 19, 2025, 12:09 PM EDT - 10 months ago

Hutchmed's Oncology Revenue Hits $271.5 Million, Rising 65% On Fruzaqla Strength

HUTCHMED Reports 2024 Full Year Results and Provides Business Updates

Mar 19, 2025, 7:00 AM EDT - 10 months ago

HUTCHMED Reports 2024 Full Year Results and Provides Business Updates

HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 Phase II/III Study of Fruquintinib and Sintilimab Combination Has Met its Primary Endpoint in Advanced Renal Cell Carcinoma in China

Mar 18, 2025, 8:00 PM EDT - 11 months ago

HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 Phase II/III Study of Fruquintinib and Sintilimab Combination Has Met its Primary Endpoint in Advanced Renal Cell Carcinoma in China

HUTCHMED Announces that it has Completed Enrollment of a Phase II Registration Study of Fanregratinib (HMPL-453) for Intrahepatic Cholangiocarcinoma in China

Mar 6, 2025, 5:00 AM EST - 11 months ago

HUTCHMED Announces that it has Completed Enrollment of a Phase II Registration Study of Fanregratinib (HMPL-453) for Intrahepatic Cholangiocarcinoma in China

HUTCHMED to Announce 2024 Final Results

Feb 19, 2025, 3:30 AM EST - 11 months ago

HUTCHMED to Announce 2024 Final Results

HUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC

Jan 13, 2025, 11:00 PM EST - 1 year ago

HUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC

Chinese Cancer Drug Developer Hutchmed Sharpens R&D Focus, Divests Non-Core JV For Over $600 Million

Jan 2, 2025, 7:38 AM EST - 1 year ago

Chinese Cancer Drug Developer Hutchmed Sharpens R&D Focus, Divests Non-Core JV For Over $600 Million

HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy

Jan 1, 2025, 7:00 PM EST - 1 year ago

HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy

Billionaire Li Ka-shing's Hutchmed in $608 mln health unit stake sales

Jan 1, 2025, 3:42 PM EST - 1 year ago

Billionaire Li Ka-shing's Hutchmed in $608 mln health unit stake sales

HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture

Jan 1, 2025, 5:46 AM EST - 1 year ago

HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture

HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib)

Dec 12, 2024, 7:00 PM EST - 1 year ago

HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib)

HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy

Dec 11, 2024, 11:00 PM EST - 1 year ago

HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy

Innovent and HUTCHMED Jointly Announce NMPA Conditional Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Advanced Endometrial Cancer

Dec 3, 2024, 7:00 PM EST - 1 year ago

Innovent and HUTCHMED Jointly Announce NMPA Conditional Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Advanced Endometrial Cancer

HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer

Dec 3, 2024, 5:00 AM EST - 1 year ago

HUTCHMED and Innovent Jointly Announce NMPA Conditional Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer

HUTCHMED Announces Continued Inclusion of ORPATHYS® (savolitinib) in the National Reimbursement Drug List in China at Current Terms

Nov 28, 2024, 5:30 AM EST - 1 year ago

HUTCHMED Announces Continued Inclusion of ORPATHYS® (savolitinib) in the National Reimbursement Drug List in China at Current Terms

HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan

Nov 21, 2024, 11:30 PM EST - 1 year ago

HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan

HUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress

Nov 5, 2024, 11:00 PM EST - 1 year ago

HUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress

HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda

Oct 31, 2024, 4:30 AM EDT - 1 year ago

HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda

HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial

Oct 16, 2024, 12:30 AM EDT - 1 year ago

HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high, clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial

topstockalerts
topstockalerts Jan. 7 at 3:25 PM
HUTCHMED announced that its Phase III ESLIM-02 trial of sovleplenib met its primary endpoint in adults with warm autoimmune hemolytic anemia (wAIHA) in China. The study showed a durable hemoglobin response between weeks 5 and 24 in patients who had relapsed or were refractory to at least one prior standard therapy. Sovleplenib, a novel spleen tyrosine kinase inhibitor, builds on strong Phase II data that demonstrated significantly higher response rates versus placebo. wAIHA is a rare but serious autoimmune disorder with limited treatment options. Investigators noted the drug’s potential to deliver rapid and sustained hemoglobin improvements. HUTCHMED plans to submit a New Drug Application for sovleplenib in wAIHA to China’s regulator in the first half of 2026 and is also advancing the drug for immune thrombocytopenia, with another NDA planned in the same timeframe. $HCM
0 · Reply
OpenOutcrier
OpenOutcrier Jan. 7 at 1:43 PM
$HCM (+5.1% pre) Hutchmed’s sovleplenib meets primary endpoint in wAIHA trial https://ooc.bz/l/88877
0 · Reply
briefingcom
briefingcom Jan. 7 at 1:31 PM
$HCM: HUTCHMED reports topline results of Phase III Part of ESLIM-02 Trial of Sovleplenib for warm antibody autoimmune hemolytic anemia in China
0 · Reply
JurisdictionJ
JurisdictionJ Dec. 27 at 9:40 AM
$HCM Sentiment increasingly tracks operational truth rather than guidance tone. Operational cadence needs to tighten meaningfully. Durability across environments would extend investor horizons. Patience is warranted — but must be supported by results.
0 · Reply
BillionerOfKing
BillionerOfKing Dec. 12 at 10:14 AM
$HCM Current Stock Price: $13.65 Contracts to trade: $17.5 HCM Dec 19 2025 Call Entry: $2.34 Exit: $3.65 ROI: 56% Hold ~26 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
QueenofSouth
QueenofSouth Dec. 11 at 11:03 PM
$HCM 10
0 · Reply
QueenofSouth
QueenofSouth Dec. 11 at 11:02 PM
$HCM 9
0 · Reply
QueenofSouth
QueenofSouth Dec. 11 at 11:02 PM
$HCM 8
0 · Reply
QueenofSouth
QueenofSouth Dec. 11 at 11:02 PM
$HCM 7
0 · Reply
QueenofSouth
QueenofSouth Dec. 11 at 11:02 PM
$HCM 6
0 · Reply
QueenofSouth
QueenofSouth Dec. 11 at 11:02 PM
$HCM 5
0 · Reply
QueenofSouth
QueenofSouth Dec. 11 at 11:02 PM
$HCM 4
0 · Reply
QueenofSouth
QueenofSouth Dec. 11 at 11:02 PM
$HCM 3
0 · Reply
QueenofSouth
QueenofSouth Dec. 11 at 11:02 PM
$HCM 2
0 · Reply
QueenofSouth
QueenofSouth Dec. 11 at 11:02 PM
$HCM 1
0 · Reply
QueenofSouth
QueenofSouth Dec. 11 at 11:02 PM
$HCM
0 · Reply
Zanetrades
Zanetrades Nov. 30 at 6:57 PM
$HCM
0 · Reply
davidmills1
davidmills1 Oct. 12 at 2:24 AM
$IMSR $HCM This one is from 2024: Terrestrial Energy Inks MOU with Schneider Electric for Data Centers: Terrestrial Energy, a developer of Generation IV advanced nuclear power plants that use its proprietary Integral Molten Salt Reactor (IMSR) technology for industrial heat and power supply, and Schneider Electric, a Fortune Global 500 supplier of digital control systems for energy management, have signed a Memorandum of Understanding (MOU) to jointly develop commercial opportunities and advance the deployment of IMSR plants.
0 · Reply
Ichigodoran
Ichigodoran Sep. 9 at 4:32 PM
$ONCY Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market $HCM $CGON $IDYA $CCCC https://barchart.com/share/news/34665959 via @Barchart
0 · Reply
EZ_Money11
EZ_Money11 Aug. 20 at 2:56 AM
$HCM 📰
0 · Reply
SorosSonosSatoshi
SorosSonosSatoshi Aug. 8 at 7:09 PM
$HCM AND 13.888
0 · Reply
SorosSonosSatoshi
SorosSonosSatoshi Aug. 8 at 7:09 PM
$HCM all eyes 13.3333
0 · Reply